A Phase II study of 13-cis-retinoic acid in patients with advanced renal cell carcinoma Academic Article Article uri icon


MeSH Major

  • Angiogenesis Inhibitors
  • Carcinoma, Renal Cell
  • Hypothyroidism
  • Indoles
  • Kidney Neoplasms
  • Pyrroles


  • The aim of this study was to determine the antitumor activity of 13-cis-retinoic acid as a single agent in patients with advanced renal cell carcinoma. Eligible patients had advanced renal cell carcinoma with bi-dimensionally measurable disease, a Karnofsky performance status of at least 70, life expectancy of greater than three months, no evidence of brain metastases, and treatment with no more than one chemotherapy regimen. Patients were treated with one mg/kg/day of 13-cis-retinoic acid orally. Twenty-six patients were enrolled in this study and 25 were evaluable for response and toxicity. Of the twenty-five evaluable patients, no major responses were achieved. Toxicity was mild, with no patient requiring a dose reduction. At the dose administered in this trial, 13-cis-retinoic acid is inactive as a single agent in renal cell carcinoma.

publication date

  • December 1997



  • Academic Article


Digital Object Identifier (DOI)

  • 10.1023/A:1005902022076

PubMed ID

  • 9547678

Additional Document Info

start page

  • 353

end page

  • 5


  • 15


  • 4